Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal

Company Milestones - Tilray Brands, Inc announced the approval of its new medical cannabis extract, Tilray Oral Solution THC10:CBD10, in Portugal, marking another milestone in its European medical cannabis operations [11] - This approval follows the earlier approval of Tilray Medical whole flower THC 18 and the first cannabis extract in Portugal earlier this year [11] Product Portfolio and Market Expansion - Tilray Medical offers a diverse portfolio of EU-GMP certified medicinal cannabis products, including Tilray, Aphria, Broken Coast, Symbios, and Navcora brands [12] - The company operates in over 20 countries across five continents, supplying medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments [12] - Tilray Medical has expanded its medical cannabis offerings in Portugal with the approval of Tilray Solução Oral THC10:CBD10, aimed at addressing specific medical conditions [1] Global Operations and Leadership - Tilray Brands, Inc is a global leader in cannabis research, cultivation, production, and distribution, with operations in Canada, the United States, Europe, Australia, and Latin America [6] - The company supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages [6] - Tilray Medical is one of the largest suppliers of medical cannabis brands globally, with a focus on safe and reliable access for patients [12] Strategic Vision and Mission - Tilray Brands aims to be the most responsible, trusted, and market-leading cannabis consumer products company globally, with a portfolio of innovative and high-quality brands [6] - The company is dedicated to transforming lives and fostering dignity for patients through safe access to medical cannabis products [12]